Sprycel receives priority review from FDA

PRINCETON, N.J. A cancer drug made by Bristol-Myers Squibb and Otsuka Pharmaceutical has received priority review from the Food and Drug Administration, the two companies said Friday.

The FDA granted priority review to the application for Sprycel (dasatinib) as a treatment for adults with newly diagnosed chronic myeloid leukemia in chronic phase. The agency is expected to reach a decision on the drug by Oct. 28.

The drug already has approval for treating adults with all phases of CML whose disease has already shown resistance to Novartis’ Gleevec (imatinib mesylate).